文献速递乳腺癌

德国辅助治疗组间淋巴结阳性研究中的高危淋巴结转移乳腺癌患者肿瘤浸润淋巴细胞、PD-1与PD-L1的相关性

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
PubMed 文献 · Eur J Cancer · 2019-05-07

该研究基于GAIN-1试验,评估1318例高危淋巴结阳性乳腺癌中肿瘤浸润淋巴细胞(TILs)与PD-1、PD-L1表达及预后的关联。TILs密度与免疫细胞PD-1、PD-L1及肿瘤细胞PD-L1表达显著相关,且在TNBC和HER2阳性肿瘤中更常见。无TILs患者中,EPC方案较EC-PwX方案DFS有不利趋势(HR=0.69,p=0.0915),而有TILs肿瘤中无差异(交互p=0.0336)。TNBC中PD-1阳性免疫细胞与显著更好的DFS相关(HR=0.50,p=0.0457)。

要点

  • TILs密度与免疫细胞PD-1、PD-L1及肿瘤细胞PD-L1表达显著相关。
  • TILs在TNBC和HER2阳性肿瘤中更常见。
  • TNBC中PD-1阳性免疫细胞与显著更好的DFS相关(HR=0.50)。

核心结论

  • TILs预测淋巴结阳性高危乳腺癌中强化ddEPC方案相较于ddEC-PwX方案的获益。
  • TILs、PD-1与PD-L1相互关联,提示肿瘤免疫原性。
  • TNBC中PD-1阳性免疫细胞具有积极的预后影响。

研究设计与样本

  • 基于德国辅助治疗组间淋巴结阳性(GAIN-1)试验,评估1318例高危淋巴结阳性乳腺癌患者。
  • 通过苏木精-伊红染色评估TILs,通过免疫组织化学(SP263检测)评估PD-1和PD-L1表达。
  • 统计检验TILs与PD-1、PD-L1、分子内在亚型、结局及治疗方案(剂量密集[dd]表柔比星、紫杉醇和环磷酰胺[EPC]与dd表柔比星、环磷酰胺、紫杉醇和卡培他滨[EC-PwX])的关联。

主要发现

  • 总体TILs密度与免疫细胞PD-1和PD-L1表达(各p<0.0001)及肿瘤细胞PD-L1表达(p=0.0051)显著相关。
  • TILs在三阴性乳腺癌(TNBC)和人表皮生长因子受体2(HER2)阳性肿瘤中更常见(各p<0.0001)。
  • 多变量Cox回归分析中,无TILs的乳腺癌患者在EPC组较EC-PwX组疾病无生存期(DFS)不利(风险比[HR]=0.69 [0.44-1.06],p=0.0915);有TILs的肿瘤中未见差异(HR=1.24 [0.92-1.67],p=0.1566,交互p=0.0336)。
  • TNBC中PD-1阳性免疫细胞与显著更好的DFS相关(HR=0.50 [0.25-0.99],p=0.0457)。
  • PD-L1表达对患者结局无影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune cell infiltration in breast cancer is important for the patient's prognosis and response to systemic therapies including immunotherapy. We sought to investigate the prevalence of tumour-infiltrating lymphocytes (TILs) and their association with immune checkpoints such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in high-risk, node-positive breast cancer of the adjuvant German Adjuvant Intergroup Node-positive (GAIN-1) trial. PATIENTS AND METHODS: We evaluated TILs by haematoxylin and eosin staining and PD-1 and PD-L1 (SP263 assay) expression by immunohistochemistry in 1318 formalin-fixed, paraffin-embedded breast carcinomas. The association of TILs with PD-1, PD-L1, molecular intrinsic subtypes, outcome and therapy regimens (dose-dense [dd] epirubicin, paclitaxel and cyclophosphamide [EPC] and dd epirubicin, cyclophosphamide, paclitaxel and capecitabine [EC-PwX]) was statistically tested. RESULTS: Overall TILs density was significantly associated with the expression of PD-1 and PD-L1 in immune cells (each p < 0.0001) and PD-L1 in tumour cells (p = 0.0051). TILs were more common in triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive tumours (each p < 0.0001). On multivariate Cox regression analyses, patients with breast cancer without TILs had an unfavourable disease-free survival (DFS) in the EPC arm compared with the EC-PwX arm (hazard ratio [HR] = 0.69 [0.44-1.06], p = 0.0915); but no differences were seen in tumours with TILs (HR = 1.24 [0.92-1.67], p = 0.1566, interaction p = 0.0336). PD-1-positive immune cells in TNBC were associated with a significantly better DFS (HR = 0.50 [0.25-0.99], p = 0.0457). PD-L1 expression had no impact on patient outcome. CONCLUSIONS: TILs predict the benefit of intensified ddEPC compared with ddEC-PwX therapy in node-positive, high-risk breast cancer. TILs, PD-1 and PD-L1 are linked to each other indicating tumour immunogenicity. Moreover, PD-1-positive immune cells have a positive prognostic impact in TNBC. CLINICAL TRIAL: NCT00196872.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Noske A, Möbus V, Weber K, et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. Eur J Cancer. 2019. PMID: 31075727. doi:10.1016/j.ejca.2019.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。